Prediction of Cerebral Hyperperfusion Syndrome After Carotid Revascularization Using Deep Learning

Recruiting Observational Study
Carotid Artery Diseases Carotid Atherosclerosis Carotid Artery Stenosis Cerebral Hyperperfusion Syndrome
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
30 – 80
Sex
Any
Study type
Observational
Participants needed
500 (estimated)
Sponsor
State Institution "Republican Scientific and Practical Center" Cardiology, Belarus · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Cerebral hyperperfusion syndrome (CHS) was initially described as a clinical complication following carotid endarterectomy (CEA), but it may occur after both CEA and carotid artery stenting. It is characterised by throbbing ipsilateral frontotemporal or periorbital headache, and sometimes diffuse headache, eye and facial pain, vomiting, confusion, macular oedema, visual disturbances, focal motor s…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Age between 30 and 80 years. 2. Occlusive-stenotic lesion of the carotid arteries with indications for carotid revascularization. Exclusion Criteria: 1. Systemic vasculitis. 2. Cerebral vessel aneurysms. 3. Arteriovenous malformation of the brain. 4. Primary brain tumor (in…
Contacts

Ivan Maiseyenka

+375333288850

i_a_moiseenko@mail.ru

CONTACT

Henadzi Popel

+375291759336

hpopel@mail.ru

CONTACT